Tesamorelin – 10MG

Why Buy Tesamorelin?

Researchers buy Tesamorelin because it is the only FDA-approved GHRH-type peptide shown to cut deep belly (visceral) fat. It is a man-made copy of Growth Hormone Releasing Hormone (GHRH). In a large clinical trial, it lowered visceral fat by about 15% over 26 weeks while the placebo group rose.^[1] It does this by triggering the body’s own pulse-style GH release, which keeps the natural feedback loop intact.

Its full GHRH sequence gives it complete action at the GHRH receptor, producing a steady, natural-style GH release that closely copies the body’s own pattern.

Benefits & Uses

Tesamorelin is mainly used to study GH release and fat reduction.^[1] Common research areas include:

• GHRH receptor action and GH pulse research
• Visceral and trunk fat reduction models
• Metabolic syndrome and body composition studies
• IGF-1 axis and downstream anabolic signaling
• Blood lipid (cholesterol/triglyceride) research
• Thinking and GH-deficient aging models

How It Works

Tesamorelin works by binding the GHRH receptor on the pituitary gland, which triggers GH release in natural pulses rather than a flat dose like injected GH. The extra GH drives the liver to make IGF-1, which helps break down fat in deep belly tissue — the basis of its FDA-approved use.^[1] In trials, lower visceral fat went along with better lipid levels.^[2] Because it keeps the natural feedback loop, it lowers the risk of GH overshoot in long-term research models.

10mg Vial Specifications

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: 5,136.8 Da
• Purity: ≥99% (third-party HPLC verified)
• Form: Lyophilized (freeze-dried) powder
• Vial Size: 10 mg
• Storage: −20 °C (long-term); 4 °C (short-term)
• Reconstitution: Bacteriostatic water

Why Choose Reviv Peptides?

Reviv Peptides supplies Tesamorelin to Canadian research institutions and researchers with third-party verified purity, full CoA paperwork, and discreet Canada-wide shipping.

Canada FAQs

Is Tesamorelin FDA-approved?

Yes. Tesamorelin (Egrifta®) is FDA-approved to treat HIV-related fat buildup (lipodystrophy).^[1] Reviv Peptides supplies the research-grade peptide.

How does it differ from CJC-1295?

The difference is the sequence. Tesamorelin uses the full 44-amino-acid GHRH sequence for complete receptor action, while CJC-1295 uses a shorter version with a DAC tag for a longer half-life. It more closely copies the body’s natural GH pattern.

Is Tesamorelin available in Canada?

Yes. Reviv Peptides ships Tesamorelin 10 mg vials across Canada.

Reconstitution & Dosing Guide

How to Reconstitute

Add 3.0 mL of bacteriostatic water to the vial. Aim the water slowly down the inside wall of the vial — do not spray it straight onto the powder. Swirl gently until it fully dissolves; do not shake. This gives about 3.33 mg/mL. Store the mixed vial at 4 °C and use within 28 days.

Low Starting Amount

• Amount per injection: 1 mg (1,000 mcg) — 30 units (0.30 mL) on a U-100 insulin syringe
• Frequency: Once daily, under the skin (evening)
• Cycle length: 12–26 weeks

The FDA-approved therapeutic dose is 2 mg daily; protocols often start at 1 mg for the first week.

Sources: [1] Falutz J, et al. Metabolic effects of a growth hormone–releasing factor (tesamorelin) in patients with HIV — NEJM / PubMed, 2007. [2] Reduction in visceral adiposity is associated with an improved metabolic profile in patients receiving tesamorelin — NIH / PMC.